ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase of Trial: Phase II
Latest Information Update: 15 May 2018
At a glance
- Drugs CB 839 (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ENTRATA
- Sponsors Calithera Biosciences
- 02 May 2018 Planned number of patients changed from 252 to 63.
- 02 May 2018 Planned End Date changed from 1 Mar 2021 to 1 Dec 2020.
- 02 May 2018 Planned primary completion date changed from 1 Mar 2020 to 1 Dec 2019.